Global Markets Direct’s, ‘Shigella Infections (Shigellosis) – Pipeline Review, H2 2015′, provides an overview of the Shigella Infections (Shigellosis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Shigella Infections (Shigellosis)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Shigella Infections (Shigellosis) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Shigella Infections (Shigellosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Shigella Infections (Shigellosis) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Shigella Infections (Shigellosis)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Shigella Infections (Shigellosis) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Shigella Infections (Shigellosis) Overview 7
Therapeutics Development 8
Pipeline Products for Shigella Infections (Shigellosis) - Overview 8
Pipeline Products for Shigella Infections (Shigellosis) - Comparative Analysis 9
Shigella Infections (Shigellosis) - Therapeutics under Development by Companies 10
Shigella Infections (Shigellosis) - Therapeutics under Investigation by Universities/Institutes 11
Shigella Infections (Shigellosis) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Shigella Infections (Shigellosis) - Products under Development by Companies 14
Shigella Infections (Shigellosis) - Products under Investigation by Universities/Institutes 15
Shigella Infections (Shigellosis) - Companies Involved in Therapeutics Development 16
Anacor Pharmaceuticals, Inc. 16
GlaxoSmithKline Plc 17
Protein Potential, LLC 18
Shigella Infections (Shigellosis) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
1790GAHB - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GVXNSD-133 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
INX-201 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
KKL-35 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SC-599 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SE-1 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
shigella vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
shigella vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Shigella Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
shigella vaccine 1 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Shigetec - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule for Shigellosis - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
typhoid + shigella vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Shigella Infections (Shigellosis) - Recent Pipeline Updates 41
Shigella Infections (Shigellosis) - Dormant Projects 42
Shigella Infections (Shigellosis) - Discontinued Products 43
Shigella Infections (Shigellosis) - Product Development Milestones 44
Featured News & Press Releases 44
Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 44
Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates 44
Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions 45
Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 46
Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 47
Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for Shigella Infections (Shigellosis), H2 2015 8
Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Shigella Infections (Shigellosis) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 16
Shigella Infections (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H2 2015 17
Shigella Infections (Shigellosis) - Pipeline by Protein Potential, LLC, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Assessment by Combination Products, H2 2015 20
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 26
Shigella Infections (Shigellosis) Therapeutics - Recent Pipeline Updates, H2 2015 41
Shigella Infections (Shigellosis) - Dormant Projects, H2 2015 42
Shigella Infections (Shigellosis) - Discontinued Products, H2 2015 43

List of Figures

Number of Products under Development for Shigella Infections (Shigellosis), H2 2015 8
Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Top 10 Targets, H2 2015 21
Number of Products by Stage and Top 10 Targets, H2 2015 21
Number of Products by Top 10 Routes of Administration, H2 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 23
Number of Products by Top 10 Molecule Types, H2 2015 25
Number of Products by Stage and Top 10 Molecule Types, H2 2015 25